Anti-TNF in small-duct PSC with IgG4 overlap

What is known

• In a retrospective PSC-IBD cohort, only adalimumab was associated with a significant ALP decrease at 6-8 months, which was not sustained at 12-24 months, with no radiological improvement. ¹
• Anti-TNF response in PSC has not been stratified by IgG4 levels to date. ¹
• In one retrospective PSC-IBD series anti-TNF agents were moderately effective without exacerbating PSC symptoms, and a signal suggests adalimumab may benefit in a way infliximab does not. ^2,3
• In liver-transplant recipients with PSC/IBD, anti-TNF worsened disease course and led to serious complications, prompting advice for a high threshold to use it. ⁴

What is unknown / caveats

• Adalimumab shows a transient ALP signal while infliximab does not ^1,3
• Anti-TNF moderately effective/safe in one PSC-IBD cohort but harmful in post-transplant PSC/IBD ^2,4
• No retrieved study stratifies anti-TNF outcomes by small-duct PSC or IgG4 status
• Available data are retrospective cohorts and case series, not prospective trials
• Biochemical (ALP) endpoints, not hard clinical outcomes or survival
• Whether a specific PSC subtype (including small-duct or IgG4-elevated) responds to anti-TNF remains unestablished and is a stated goal of future study.

References

1. Manganis CD, Chapman RW, Culver EL. Review of primary sclerosing cholangitis with increased IgG4 levels. World J Gastroenterol. 2020. PMID: 32684731.

2. Hedin CRH, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum BA, van Munster KN, Ponsioen CY, Levy C, Nogueira NF, Bowlus CL, Gotlieb N, Shibolet O, Lynch KD, Chapman RW, Rupp C, Vesterhus M, Jørgensen KK, Rorsman F, Schramm C, Sabino J, Vermeire S, Zago A, Cazzagon N, Marschall HU, Ytting H, Ben Belkacem K, Chazouilleres O, Almer S, International PSC Study G, Bergquist A. Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2020. PMID: 32068151.

3. Lynch KD, Keshav S, Chapman RW. The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis. Curr Hepatol Rep. 2019. PMID: 31008013.

4. Parekh R, Abdulhamid A, Trudeau S, Kaur N. Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis. Case Rep Gastrointest Med. 2018. PMID: 29862092.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct.